Summer Sale Get Elite for just $199.50

00

Days

00

Hours

00

Mins

00

Sec

Claim Now

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Latest News

Jun-29	BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns ALKS Investing.com
Jun-29	Adobe downgraded, Roblox upgraded: Wall Street's top analyst calls ALKS The Fly
Jun-26	Alkermes incoming CEO has a plan to outplay Lilly and Takeda ALKS BioPharma Dive
Jun-25	Qualcomm upgrade, Intel initiation among today's top calls on Wall Street EXEL The Fly
Jun-23	Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View KNSA Investor's Business Daily
Jun-23	Biotech Kiniska Pushes Toward A Buy Zone With Blockbuster Drug Sales In View KNSA Investor's Business Daily
Jun-22	Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer EXEL Business Wire
Jun-17	Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 ALKS Business Wire
Jun-15	Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe ALKS Business Wire
Jun-12	Rapport fully prepared to launch seizure drug solo, CEO says ALKS BioPharma Dive
Jun-10	Exelixis Hits High on Growing Sales, Institutional Inflows EXEL FX Empire
Jun-04	Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research ALKS Business Wire
Jun-03	Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference ALKS Business Wire
May-31	Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma IMCR GlobeNewswire
May-30	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 EXEL Business Wire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)